Purvalanol A, a Cdc2 / Cdk1 inhibitor, potentiates the cytotoxicity of Paclitaxel on non-small cell lung cancer cells in vitro by targeting Op18/stathmin [48]. Here, STMN1 is linked to non-small cell lung carcinoma.